Lira Pharma: what changed
What changed
Lira Pharma
NACE 64.210, Activities of holding companies
filed annual accounts (NBB)
Net result for the year
€210,951
2024 · €186,965+€23,986
Equity
€1.4m
2024 · €1.2m+€210,951
Cash
€71,640
2024 · €85,901-€14,262
Balance sheet total
€2.7m
2024 · €2.7m+€37,060
Largest movements
Assets
- Receivables within one year +€49,286
up €49,286 (+272%), from €18,150 to €67,436
of which Other amounts receivable: +€49,286
Equity and liabilities
- Reserves +€210,951
up €210,951 (+17.5%), from €1.2m to €1.4m
- Debts after one year -€176,886
down €176,886 (-14.0%), from €1.3m to €1.1m
Income statement
- Gross operating margin +€29,210
up €29,210 (+9.7%), from €301,341 to €330,551
- Taxes +€11,194
up €11,194 (+13.8%), from €81,055 to €92,249
- Financial charges -€6,062
down €6,062 (-18.3%), from €33,118 to €27,056
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2024
€186,965
Gross operating margin
+€29,210
Other operating charges
-€93
Financial charges
+€6,062
Taxes
-€11,194
Result 2025
€210,951
raises the resultlowers the result
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
From operations
+€159,903
Investment
€0
Financing
-€174,165
Cash 2024
€85,901
From operations (derived)
+€159,903
Net result for the year
+€210,951
Receivables within one year
-€49,286
Deferred charges and accrued income
-€2,035
Trade debts
+€73
Tax, wage and social debts
+€7,222
Other debts
-€1,399
Accrued charges and deferred income
-€5,622
Financing
-€174,165
Debts after one year
-€176,886
Current portion of long-term debt
+€2,721
Cash 2025
€71,640
brings cash intakes cash out
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,687,778 | €2,724,838 | +€37,060 | +1.4% |
| Fixed assets | 21/28 | €2,583,372 | €2,583,372 | = | 0.0% |
| Financial fixed assets | 28 | €2,583,372 | €2,583,372 | = | 0.0% |
| Current assets | 29/58 | €104,406 | €141,466 | +€37,060 | +35.5% |
| Amounts receivable within one year | 40/41 | €18,150 | €67,436 | +€49,286 | +272% |
| Trade receivables | 40 | €18,150 | €18,150 | = | 0.0% |
| Other amounts receivable | 41 | €0 | €49,286 | +€49,286 | |
| Cash at bank and in hand | 54/58 | €85,901 | €71,640 | -€14,262 | -16.6% |
| Deferred charges and accrued income | 490/1 | €355 | €2,390 | +€2,035 | +573% |
| Total equity and liabilities | 10/49 | €2,687,778 | €2,724,838 | +€37,060 | +1.4% |
| Equity | 10/15 | €1,226,906 | €1,437,857 | +€210,951 | +17.2% |
| Contributions | 10/11 | €18,550 | €18,550 | = | 0.0% |
| Reserves | 13 | €1,208,356 | €1,419,307 | +€210,951 | +17.5% |
| Distributable reserves | 133 | €1,208,356 | €1,419,307 | +€210,951 | +17.5% |
| Amounts payable | 17/49 | €1,460,872 | €1,286,981 | -€173,891 | -11.9% |
| Amounts payable after more than one year | 17 | €1,261,528 | €1,084,641 | -€176,886 | -14.0% |
| Financial debts | 170/4 | €1,261,528 | €1,084,641 | -€176,886 | -14.0% |
| Amounts payable within one year | 42/48 | €189,514 | €198,131 | +€8,616 | +4.5% |
| Current portion of amounts payable after more than one year | 42 | €148,165 | €150,886 | +€2,721 | +1.8% |
| Trade debts | 44 | €1,382 | €1,454 | +€73 | +5.3% |
| Suppliers | 440/4 | €1,382 | €1,454 | +€73 | +5.3% |
| Taxes, remuneration and social security | 45 | €37,358 | €44,580 | +€7,222 | +19.3% |
| Taxes | 450/3 | €37,358 | €44,580 | +€7,222 | +19.3% |
| Other amounts payable | 47/48 | €2,609 | €1,210 | -€1,399 | -53.6% |
| Accrued charges and deferred income | 492/3 | €9,830 | €4,209 | -€5,622 | -57.2% |
| Other operating charges | 640/8 | €203 | €296 | +€93 | +45.7% |
| Gross operating margin | 9900 | €301,341 | €330,551 | +€29,210 | +9.7% |
| Operating profit (loss) | 9901 | €301,138 | €330,255 | +€29,118 | +9.7% |
| Financial charges | 65/66B | €33,118 | €27,056 | -€6,062 | -18.3% |
| Recurring financial charges | 65 | €33,118 | €27,056 | -€6,062 | -18.3% |
| Profit (loss) for the period before taxes | 9903 | €268,020 | €303,200 | +€35,180 | +13.1% |
| Income taxes | 67/77 | €81,055 | €92,249 | +€11,194 | +13.8% |
| Profit (loss) for the period | 9904 | €186,965 | €210,951 | +€23,986 | +12.8% |
| Profit (loss) for the period to be appropriated | 9905 | €186,965 | €210,951 | +€23,986 | +12.8% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 5 November 2026 via checked.be.